Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Catalio Capital Management, LP
Form 13F · Q2 2026

Catalio Capital Management, LP

CIK 1958125Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$532M
Reported book value
39
Positions
7
Quarters on record
Top 50
Positions

Catalio Capital Management, LP — holdings

Top 39 positions of 39, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1AVLN Avalyn Pharmaceuticals Inc1.7M—$55M10.4%
2JNJ Johnson & Johnson138,946—$35M6.6%
3GILD Gilead Sciences Inc269,309+64.3%$34M6.4%
4BBIO Bridgebio Pharma Inc455,041+5.3%$34M6.4%
5SNDX Syndax Pharmaceuticals Inc1.2M+16.5%$27M5.0%
6DFTX Definium Therapeutics Inc562,672−45.8%$26M5.0%
7BMY Bristol-Myers Squibb Co412,961−1.8%$24M4.5%
8PBLS Parabilis Medicines Inc824,043—$23M4.2%
9NTRA Natera Inc82,181+15.9%$22M4.2%
10INCY Incyte Corp191,627+5.2%$22M4.1%
11SEPN Septerna Inc536,152+82.1%$18M3.4%
12MLYS Mineralys Therapeutics Inc648,722+47.8%$18M3.3%
13HTFL Heartflow Inc583,055+44.5%$17M3.2%
14CRVS Corvus Pharmaceuticals Inc1.1M+21.2%$16M3.0%
15GPCR Structure Therapeutics Inc276,550+8.3%$15M2.8%
16PTGX Protagonist Therapeutics Inc106,799—$13M2.5%
17IRON Disc Medicine Inc159,384+29.6%$12M2.2%
18EW Edwards Lifesciences Corp124,778−13.7%$11M2.1%
19AXSM Axsome Therapeutics Inc.43,182—$11M2.0%
20RARE Ultragenyx Pharmaceutical In316,252−62.8%$11M2.0%
21KLRA Kailera Therapeutics Inc468,750—$10M1.9%
22KPTIQ Karyopharm Therapeutics Inc940,855+4.8%$9M1.7%
23ODTX Odyssey Therapeutics Inc457,839—$9M1.6%
24ASND Ascendis Pharma A/S31,759—$8M1.6%
25KARD Kardigan Inc312,500—$7M1.4%
26ELDN Eledon Pharmaceuticals Inc1.7M+3.4%$7M1.3%
27FDMT 4D Molecular Therapeutics In471,254—$6M1.2%
28MANE Veradermics Inc45,856−73.6%$6M1.1%
29DYN Dyne Therapeutics Inc244,929−13.4%$5M1.0%
30GUTS Fractyl Health Inc6.2M+12.3%$5M0.9%
31IMCR Immunocore Hldgs Plc148,045+75.5%$5M0.9%
32DNTH Dianthus Therapeutics Inc32,941−94.1%$3M0.6%
33BBOT Bridgebio Oncology Therapeut318,407—$2M0.5%
34TARA Protara Therapeutics Inc520,148−10.3%$2M0.4%
35HYPR Hyperfine Inc1.3M+0.0%$2M0.3%
36ATAIBECKLEY INC Ataibeckley Inc196,858+0.0%$1M0.2%
37MGX Metagenomi Therapeutics Inc528,993+0.0%$629,5020.1%
38OM Outset Med Inc118,279+0.0%$510,9650.1%
39FTH Faeth Therapeutics Inc14,718+0.0%$367,9500.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.